Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
Substantial |
The actual benefit of ACTILYSE 2 mg is substantial.
|
Clinical Added Value
minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE.
|
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
C5DwJaVHYCjw0fh4